Who is sponsoring NCT07244341?

NCT07244341 is sponsored by Daiichi Sankyo.

What drugs are being tested in NCT07244341?

Interventions in NCT07244341: Valemetostat, Darolutamide.

What condition does NCT07244341 study?

NCT07244341 studies Metastatic Castration-resistant Prostate Cancer.

Is NCT07244341 still recruiting?

NCT07244341 is currently recruiting now. Last updated 4 February 2026.

Last reviewed 2026-02-04 · How we verify

NCT07244341

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Recruiting now Phase 1 Last updated 4 February 2026

What this trial tests

Phase 1 trial testing Valemetostat in Metastatic Castration-resistant Prostate Cancer in 60 participants. Currently enrolling.

Timeline

3 December 2025

Primary endpoint
31 January 2028

30 November 2029

Quick facts

Lead sponsor	Daiichi Sankyo
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	3 December 2025
Primary completion	31 January 2028
Estimated completion	30 November 2029
Sites	6 locations across Japan, United States

Drugs / interventions tested

Valemetostat (VALEMETOSTAT) — full drug profile →
Darolutamide (darolutamide) — full drug profile →

Conditions studied

Metastatic Castration-resistant Prostate Cancer — all drugs for Metastatic Castration-resistant Prostate Cancer →

Sponsor

Daiichi Sankyo — full company profile →

Who can join

18 and older, male only, with Metastatic Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Valemetostat

Trials testing the same drug.

NCT06294548 — A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC · Phase 1, PHASE2 · recruiting
NCT05683171 — A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory F · Phase 1, PHASE2 · recruiting
NCT05633979 — Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ult · Phase 1 · active not recruiting
NCT04388852 — DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers · Phase 1 · active not recruiting
NCT03930953 — A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants · Phase 1, PHASE2 · active not recruiting

Other recruiting trials for Metastatic Castration-resistant Prostate Cancer

Currently open trials in the same condition.

NCT07142551 — Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response · Phase 2 · recruiting
NCT07288359 — Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and · Phase 1, PHASE2 · recruiting
NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic · Phase 3 · recruiting
NCT07189403 — A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resist · Phase 1 · recruiting
NCT06922318 — The COSMYC Trial (COmbined Suppression of MYC) · Phase 2 · recruiting

Other Daiichi Sankyo trials

Trials by the same sponsor.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07206472 — A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholestero · active not recruiting
NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
NCT07268625 — Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorv · Phase 1 · completed
NCT07189403 — A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resist · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07244341 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daiichi Sankyo
Last refreshed: 4 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07244341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing